2022-502380-37-00招募中3 期
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 167
- 试验地点
- 28
- 主要终点
- Duration of effect of Bimatoprost SR
研究概览
简要总结
To evaluate the duration of IOP-lowering effect of Bimatoprost SR in participants with OAG or OHT who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Fellow eye treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Participant must be at least 18 years of age at the time of signing the informed consent
- •In the investigator's opinion, the study eye can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog (eg, LUMIGAN, Xalatan, Travatan) eye drops as the sole therapy if medication was taken as directed
- •The iridocorneal angle in the study eye must be, in the opinion of the investigator, able to safely receive at least 1 Bimatoprost SR implant using the following criteria: a. Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior angle b. Peripheral anterior chamber depth by Van Herick examination ≥ ½ corneal thickness
- •At the Baseline visit, participant has been appropriately washed out of all IOPlowering medications
- •At the Baseline visit (9:00 AM ± 1 hour), IOP of ≥ 22 and ≤ 34 mm Hg in the study eye
- •Central corneal endothelial cell density by specular microscopy deemed acceptable, in the opinion of the investigator (at Screening, a minimum endothelial cell density of 2000 cells/mm2 in the study eye by automated analysis)
- •At the Baseline visit: BCVA (Snellen equivalent, by manifest refraction) of 20/50 or better in the study eye and 20/100 or better in the fellow eye
- •Male or female
- •Written informed consent and authorization for use and release of personal health information are obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]) Participants must not be incarcerated and must be freely willing and able to provide informed consent (eg, adults under legal protection measure [eg, under guardianship/curatorship] or unable to express their consent and select adults under psychiatric care are not eligible). Investigator's discretion should be applied.
- •Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow up period
- •A female participant is eligible to participate if she is not pregnant (ie, has a negative urine pregnancy result at Baseline), not breastfeeding, and at least one of the following conditions applies: a. Not a WOCBP as defined in Appendix 7 of the protocol OR b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 7 of the protocol during the study period
- •Participant is willing to withhold his/her IOP treatments according to the study requirements, and in the opinion of the investigator, can do so without significant risk. Note: If participants cannot discontinue their currently prescribed therapy for up to 8 weeks to meet the Washout period for study entry, the investigator may switch the participant's medication to one that requires a shorter washout interval during the washout of the original medication.
- •Participant has the ability to understand and willingness to follow study instructions and is likely to complete all required visits and procedures
- •In the investigator's opinion, participant's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence)
- •Diagnosis of either OAG (ie, primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or OHT in the study eye, requiring IOP-lowering treatment
排除标准
- •Uncontrolled systemic disease
- •The following surgical history in the study eye: a. History or evidence of complicated cataract/lens surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant [IOL], sulcus IOL, aphakia, etc.) or intraoperative complications (such as a posterior capsular tear [with or without vitreous loss], substantial iris trauma, etc.) Note: history of uncomplicated cataract surgery is not an exclusion b. History of phakic IOL insertion for refractive error correction
- •Intraocular surgery (including cataract surgery) in the study eye within the 6 months prior to treatment administration (Day 1 Cycle 1 Administration)
- •Any history of corneal graft, including partial grafts (eg, Descemet's Stripping Endothelial Keratoplasty [DSEK], Descemet's Membrane Endothelial Keratoplasty [DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions in the study eye
- •Central corneal thickness of < 480 or > 620 micrometers in the study eye
- •Females who are pregnant, nursing, or planning a pregnancy during the study OR who are WOCBP and will not follow contraceptive guidance
- •Known allergy or sensitivity to any study medication or its components, any component of the delivery vehicle, procedure-related materials, or diagnostic agents used during the study (eg, topical anesthetic, dilating drops, fluorescein, povidone-iodine)
- •Participants who have a condition or are in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study;Note: the investigator should consider a participant's overall health condition, including COVID-19 infection. This should include assessing if the patient is suspected of; quarantined for; or diagnosed with active COVID-19 infection, and whether or not the participant has any symptoms
- •Concurrent or anticipated enrollment in an investigational drug or device study or participation in such a study within 2 months prior to the Baseline visit through the final study visit
- •Previous use of commercially available Bimatoprost SR in the study eye; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which a Bimatoprost SR implant was received in the study eye. Note: Participants with an eye that has not been previously treated with Bimatoprost SR or participants previously enrolled in Bimatoprost SR studies 192024-091/-092, and -041D who have an eye that was not treated with Bimatoprost SR in that study may be enrolled, provided that the eye that did not receive Bimatoprost SR meets entry criteria for this study
- •Known history of bleeding disorder or prolonged bleeding after surgery (in the opinion of the investigator) Note: Participants receiving pharmacologic blood thinners (eg, aspirin, Coumadin) may be enrolled at the investigator's discretion
- •History of previous laser trabeculoplasty in the study eye
- •History or evidence of clinically relevant, substantial ocular trauma (eg, a traumatic cataract, traumatic angle recession, etc.) in the study eye
结局指标
主要结局
Duration of effect of Bimatoprost SR
Duration of effect of Bimatoprost SR
次要结局
- Adverse events; visual fields; visual acuity; macroscopic bulbar conjunctival hyperemia; slit-lamp biomicroscopic assessments; dilated ophthalmoscopic assessments (including optic disc assessment); contact ultrasound pachymetry; gonioscopy; specular microscopy
研究者
Global Clinical Trials Contact
Scientific
Abbvie Deutschland GmbH & Co. KG
研究点 (28)
Loading locations...
相似试验
招募中
4 期
OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness2024-511581-37-00OM Pharma SA497
招募中
3 期
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC)2025-520927-26-00Janssen Cilag International247
招募中
1 期
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid TumorsNCT07299747VelaVigo Bio Inc255
招募中
2 期
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients2024-519481-44-00Gruppo Oncologico Dell'Italia Meridionale173
招募中
2 期
A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis2024-520201-39-00Odyssey Therapeutics Inc.47